PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

Recruiting now · Phase 2

Conditions studied: Pancreatic Cancer

In brief

This is an open-label, phase II study in patients with resectable and borderline resectable pancreatic cancer.

Key facts

Study ID

NCT04683315

Run by

Medical College of Wisconsin

People needed

84

Starts

2021-04-01

Expected to finish

2028-12-31

Last updated by the study team

2026-03-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Has received chemotherapy and/or radiation within three years prior to study enrollment.
• Has any previous history of another malignancy (other than cured basal or squamous cell carcinoma of the skin or cured in situ carcinoma of the cervix or localized prostate cancer with normal prostate specific antigen) within three years of study enrollment.
• Uncontrolled comorbidities including, but not limited to, ongoing or active serious infection, symptomatic congestive heart failure, unstable angina, unstable cardiac arrhythmias, psychiatric illness, excessive obesity (BMI >55) or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent.
• Known HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
• Pregnant or breastfeeding patients or any patient with childbearing potential not using contraception four weeks prior to treatment.

Where it is running

• HonorHealth Medical Group — Scottsdale, Arizona, United States (enrolling)
• Froedtert & the Medical College of Wisconsin — Milwaukee, Wisconsin, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.